02/06/2026 – Stonegate Capital Partners updates its coverage of AB Science’s stock with a discounted cash flow valuation mid-point of EUR 4.25 per share Download PDF Category: 20262 June 2026Post navigationPreviousPrevious post:AB Science announces that its stock continues to be covered by Maxim Group, with a target price of €4.00 per shareNextNext post:AB Science is invited to present at the 2026 ENCALS annual meeting the survival data from masitinib clinical program in ALSRelated PostsAB Science web conference of October 14, 202614 October 2026Web conference on October 14, 2026, from 6:00 p.m. to 7:30 p.m.12 October 2026Revenues for the first half of 2026 and update on AB Science’s activities9 October 2026AB Science provides an update on its development plan and financial calendar following a sponsor Good Clinical Practice inspection29 September 2026AB Science announces the successful settlement and delivery of securities issued as part of its €14.2 million private placement announced on August 10, 202617 August 2026AB Science announces the successful completion of capital increases of a total gross amount of EUR 14.2 million10 August 2026
AB Science provides an update on its development plan and financial calendar following a sponsor Good Clinical Practice inspection29 September 2026
AB Science announces the successful settlement and delivery of securities issued as part of its €14.2 million private placement announced on August 10, 202617 August 2026
AB Science announces the successful completion of capital increases of a total gross amount of EUR 14.2 million10 August 2026
